The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
Open accessAbstract
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A–D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer’s disease (A), memantine for moderate to severe Alzheimer’s disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer’s disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson’s disease dementia and dementia with Lewy bodies), and memantine may be helpful (A). No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B). Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer’s disease are in progress. Though results of pivotal studies in early (prodromal/mild) Alzheimer’s disease are awaited, results to date in more established (mild to moderate) Alzheimer’s disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“, 2011), mild cognitive impairment due to AD (Albert et al., 2011) and preclinical AD (Sperling et al.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationRomán, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationResearch criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Self-citationNgandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 1×
“There is Level 1 evidence from an RCT that met its primary outcome that a combination of diet, cognitive training, cardiovascular health optimisation and exercise can slow cognitive decline in an at-risk elderly population (Ngandu et al., 2015), though the contribution of each factor within the FINGER multi-modal inte…”
BackgroundAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationMendelson, G. (1995) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679509064964 · Cited by 2,858
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“An exploratory analysis showed better clinical outcomes in patients who did not carry the APOE e4 allele which led to two large RPCTs of bapineuzumab in APOE e4 positive and negative AD subjects (Salloway et al., 2014).”
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“, 2007), which were later expanded to include prodromal AD (Dubois et al., 2010) and further revised to include amyloid imaging (Dubois et al.”
BackgroundSelf-citationDoody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Self-citationKnopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410 · cited 2×
“, 2007), the American Academy of Neurology (Knopman et al., 2001) and the Scottish Intercollegiate Guidelines network (SIGN; www.”
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Self-citationSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Self-citationCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
(2014) · International Journal of Stroke · doi:10.1111/ijs.12374_18 · Cited by 1,166
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Self-citationO'Brien, J. T., & Thomas, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00463-8 · Cited by 1,136
Self-citationCumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111 · cited 1×
“, 2013a) and with increased risk for dementia (Gray et al., 2015).”
BackgroundImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
Self-citation(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1069 · Cited by 988
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement
Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., Blazer, D. G., Chen, C., Chui, H., et al. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000034 · Cited by 852
Self-citationDonepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
Self-citationDurga, J., van Boxtel, M. P., Schouten, E. G., Kok, F. J., Jolles, J., Katan, M. B., & Verhoef, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60109-3 · Cited by 758
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 727
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Self-citationMcKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., Bonuccelli, U., Volterrani, D., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70057-1 · Cited by 716
Self-citationPrevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Self-citationDeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 670
Fox, C., Richardson, K., Maidment, I. D., Savva, G. M., Matthews, F. E., Smithard, D., Coulton, S., Katona, C., Boustani, M. A., & Brayne, C. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03491.x · Cited by 655
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Self-citationWaldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Self-citationHorvath, J. C., Forte, J. D., & Carter, O. (2015) · Brain Stimulation · doi:10.1016/j.brs.2015.01.400 · Cited by 609
Ancelin, M. L., Artero, S., Portet, F., Dupuy, A.-M., Touchon, J., & Ritchie, K. (2006) · BMJ · doi:10.1136/bmj.38740.439664.de · Cited by 589
Ginkgo biloba for cognitive impairment and dementia
Birks, J., & Grimley Evans, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 581
Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011) · BMJ · doi:10.1136/bmj.d4065 · Cited by 571
Aisen, P. S. (2008) · JAMA · doi:10.1001/jama.300.15.1774 · Cited by 557
Salahudeen, M. S., Duffull, S. B., & Nishtala, P. S. (2015) · BMC Geriatrics · doi:10.1186/s12877-015-0029-9 · Cited by 547
World Alzheimer Report 2011 : The benefits of early diagnosis and intervention
Prince, M. J., Bryce, R., & Ferri, C. P. (2018) · Cited by 539
Conversion of amyloid positive and negative MCI to AD over 3 years: An 11 C-PIB PET study
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Någren, K., Bullock, R., Walker, Z., Kennedy, A., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 527
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Self-citationTo: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 489
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70146-2 · Cited by 459
Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., Tolosa, E., Kutzelnigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., & Jones, R. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70194-0 · Cited by 436
Self-citationKuo, M.-F., Paulus, W., & Nitsche, M. A. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.117 · Cited by 415 · cited 1×
“) has suggested that non-invasive stimulation techniques can have effects which are sustained beyond the period of the stimulation and this clearly has important therapeutic ramifications (Elder and Taylor, 2014; Hsu et al., 2015; Kuo et al., 2014).”
BackgroundHorvath, J. C., Carter, O., & Forte, J. D. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00002 · Cited by 414
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402 · cited 1×
“Thus a large trial of rofecoxib found an increased risk of conversion to AD in the MCI-treated group (Thal et al., 2005).”
BackgroundFrontotemporal Dementia: A Randomised, Controlled Trial with Trazodone
Lebert, F., Stekke, W., Hasenbroekx, C., & Pasquier, F. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000077171 · Cited by 382
Burton, E. J., Barber, R., Mukaetova-Ladinska, E. B., Robson, J., Perry, R. H., Jaros, E., Kalaria, R. N., & O’Brien, J. T. (2009) · Brain · doi:10.1093/brain/awn298 · Cited by 370
Self-citationRiluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2009) · Brain · doi:10.1093/brain/awn291 · Cited by 347
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341
Hsu, W.-Y., Ku, Y., Zanto, T. P., & Gazzaley, A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.016 · Cited by 330
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327
Self-citationGalantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
Dodel, R. C. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317
McGuinness, B., Todd, S., Passmore, P., & Bullock, R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub3 · Cited by 315
Self-citationVascular factors predict rate of progression in Alzheimer disease
Mielke, M. M., Rosenberg, P. B., Tschanz, J., Cook, L., Corcoran, C., Hayden, K. M., Norton, M., Rabins, P. V., Green, R. C., Welsh-Bohmer, K. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279520.59792.fe · Cited by 309
Gill, S. S., Anderson, G. M., Fischer, H. D., Bell, C. M., Li, P., Normand, S.-L. T., & Rochon, P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.43 · Cited by 306
Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial
Scheltens, P., Twisk, J. W. R., Blesa, R., Scarpini, E., von Arnim, C. A. F., Bongers, A., Harrison, J., Swinkels, S. H. N., Stam, C. J., de Waal, H., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121189 · Cited by 306
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial
Scheltens, P., Kamphuis, P. J. G. H., Verhey, F. R. J., Olde Rikkert, M. G. M., Wurtman, R. J., Wilkinson, D., Twisk, J. W. R., & Kurz, A. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.10.003 · Cited by 299
Effects of Ginkgo biloba in dementia: systematic review and meta-analysis
Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C., & Willich, S. N. (2010) · BMC Geriatrics · doi:10.1186/1471-2318-10-14 · Cited by 297
Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 290
Malouf, R., & Grimley Evans, J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004514.pub2 · Cited by 277
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Wang, H.-F., Yu, J.-T., Tang, S.-W., Jiang, T., Tan, C.-C., Meng, X.-F., Wang, C., Tan, M.-S., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307659 · Cited by 269
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000231744.69631.33 · Cited by 267
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Aβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
Self-citationPharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis
Stinton, C., McKeith, I., Taylor, J.-P., Lafortune, L., Mioshi, E., Mak, E., Cambridge, V., Mason, J., Thomas, A., & O’Brien, J. T. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121582 · Cited by 264
Self-citationDichgans, M., Markus, H. S., Salloway, S., Verkkoniemi, A., Moline, M., Wang, Q., Posner, H., & Chabriat, H. S. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70046-2 · Cited by 264
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
Collinge, J., Gorham, M., Hudson, F., Kennedy, A., Keogh, G., Pal, S., Rossor, M., Rudge, P., Siddique, D., Spyer, M., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70049-3 · Cited by 262
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 248
Self-citationMazza, M., Capuano, A., Bria, P., & Mazza, S. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01409.x · Cited by 237
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59bf3 · Cited by 232
Nimodipine for primary degenerative, mixed and vascular dementia
Birks, J., & López-Arrieta, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000147 · Cited by 230
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228 · cited 1×
“New RCTs of memantine in FTD report a lack of efficacy with this drug (Boxer et al., 2013; Vercelletto et al., 2011).”
BackgroundRahman, S., Nestor, P. J., Hodges, J. R., Sahakian, B. J., & Deakin, J. B. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1686-5 · Cited by 221
Gauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Hormone replacement therapy for cognitive function in postmenopausal women
Lethaby, A., Hogervorst, E., Richards, M., Yesufu, A., & Yaffe, K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003122.pub2 · Cited by 214
Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria
Aarsland, D., Rongve, A., Piepenstock Nore, S., Skogseth, R., Skulstad, S., Ehrt, U., Hoprekstad, D., & Ballard, C. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000165917 · Cited by 208
Autonomic dysfunction in dementia with Lewy bodies
Thaisetthawatkul, P., Boeve, B. F., Benarroch, E. E., Sandroni, P., Ferman, T. J., Petersen, R., & Low, P. A. (2004) · Neurology · doi:10.1212/01.wnl.0000125192.69777.6d · Cited by 208
Haïk, S., Marcon, G., Mallet, A., Tettamanti, M., Welaratne, A., Giaccone, G., Azimi, S., Pietrini, V., Fabreguettes, J.-R., Imperiale, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70307-7 · Cited by 203
Ritchie, C. W., Molinuevo, J. L., Truyen, L., Satlin, A., Van der Geyten, S., & Lovestone, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00454-x · Cited by 202
Self-citationSKOOG, I., LITHELL, H., HANSSON, L., ELMFELDT, D., HOFMAN, A., OLOFSSON, B., TRENKWALDER, P., & ZANCHETTI, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.02.013 · Cited by 199
Holmes, H. M., Sachs, G. A., Shega, J. W., Hougham, G. W., Cox Hayley, D., & Dale, W. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01741.x · Cited by 195
Applegate, W. B. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420190047006 · Cited by 193
18F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias
O’Brien, J. T., Firbank, M. J., Davison, C., Barnett, N., Bamford, C., Donaldson, C., Olsen, K., Herholz, K., Williams, D., & Lloyd, J. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.143347 · Cited by 192
Self-citationGalantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
The role of levodopa in the management of dementia with Lewy bodies
Molloy, S. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.052332 · Cited by 187
Role of imaging techniques in the diagnosis of dementia
O'BRIEN, J. T. (2007) · The British Journal of Radiology · doi:10.1259/bjr/33117326 · Cited by 187
Self-citationValue of 123 I-MIBG radioactivity in the differential diagnosis of DLB from AD
Yoshita, M., Taki, J., Yokoyama, K., Noguchi-Shinohara, M., Matsumoto, Y., Nakajima, K., & Yamada, M. (2006) · Neurology · doi:10.1212/01.wnl.0000219640.59984.a7 · Cited by 185
Schneider, L., DeKosky, S., Farlow, M., Tariot, P., Hoerr, R., & Kieser, M. (2005) · Current Alzheimer Research · doi:10.2174/156720505774932287 · Cited by 182
A feasibility and tolerability study of lithium in Alzheimer's disease
Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 175
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease
Geschwind, M. D., Kuo, A. L., Wong, K. S., Haman, A., Devereux, G., Raudabaugh, B. J., Johnson, D. Y., Torres-Chae, C. C., Finley, R., Garcia, P., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a9f3b4 · Cited by 175
Gauthier, S., & Schlaefke, S. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s72728 · Cited by 174
Samuel, W., Caligiuri, M., Galasko, D., Lacro, J., Marini, M., McClure, F. S., Warren, K., & Jeste, D. V. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200009)15:9<794::aid-gps178>3.0.co;2-1 · Cited by 174
Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2003) · European Neurology · doi:10.1159/000067021 · Cited by 172
Donepezil for mild cognitive impairment
Birks, J., & Flicker, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006104 · Cited by 169
Moving Us Toward a Theory of Individual Quality of Life
Schalock, R. L., Verdugo, M. A., Gomez, L. E., & Reinders, H. S. (2016) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-121.1.1 · Cited by 169
Malouf, R., & Areosa Sastre, A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004394 · Cited by 168
Burns, A. S., O'Brien, J. T., Auriacombe, S., Ballard, C., Broich, K., Bullock, R., Feldman, H., Ford, G., Knapp, M., McCaddon, A., et al. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106068299 · Cited by 167
Self-citationHoward, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 165
Self-citationYoshita, M., Arai, H., Arai, H., Arai, T., Asada, T., Fujishiro, H., Hanyu, H., Iizuka, O., Iseki, E., Kashihara, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120540 · Cited by 165
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H., Edland, S. D., Teng, E., Tingus, K., Petersen, R. C., & Cummings, J. L. (2009) · Neurology · doi:10.1212/wnl.0b013e3181aa52d3 · Cited by 164
Elder, G. J., & Taylor, J.-P. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0074-1 · Cited by 164
Self-citationO’Brien, J. T., & Burns, A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110387547 · Cited by 164
Self-citationHormone replacement therapy to maintain cognitive function in women with dementia
Hogervorst, E., Yaffe, K. S., Richards, M., & Huppert, F. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003799.pub2 · Cited by 163
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan, I., Phipps, M., Pharr, V. L., Hallett, M., Grafman, J., & Salazar, A. (2001) · Neurology · doi:10.1212/wnl.57.3.467 · Cited by 163
A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline
Dodge, H. H., Zitzelberger, T., Oken, B., Howieson, D. B., & Kaye, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000303814.13509.db · Cited by 162
Dementia before Death in Ageing Societies— The Promise of Prevention and the Reality
Brayne, C., Gao, L., Dewey, M., Matthews, F. E., & Medical Research Council Cognitive Function and Ageing Study Investigators (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030397 · Cited by 158
Modelling Mini Mental State Examination changes in Alzheimer's disease
Mendiondo, M. S., Ashford, J. W., Kryscio, R. J., & Schmitt, F. A. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000615/30)19:11/12<1607::aid-sim449>3.0.co;2-o · Cited by 153
Stamelou, M., Reuß, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade‐Brittinger, C., Oertel, W. H., et al. (2008) · Movement Disorders · doi:10.1002/mds.22023 · Cited by 152
Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on
Maki, P. M., & Henderson, V. W. (2012) · Climacteric · doi:10.3109/13697137.2012.660613 · Cited by 152
† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 152
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
Suemoto, C. K., Apolinário, D., Nakamura-Palacios, E. M., Lopes, L. D. C., Leite, R. E. P., Sales, M. V. C., Nitríni, R., Brucki, S. M. D., Morillo, L. S., Magaldi, R. M., et al. (2013) · Brain stimulation · doi:10.1016/j.brs.2013.10.003 · Cited by 150
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802328142 · Cited by 147
Rahman, S., Robbins, T. W., Hodges, J. R., Mehta, M. A., Nestor, P. J., Clark, L., & Sahakian, B. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300886 · Cited by 144
Robinson, L. A., Iliffe, S., Brayne, C., Goodman, C. M., Rait, G., Manthorpe, J., Ashley, P., & Moniz-Cook, E. D. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2405 · Cited by 141
Self-citationSchmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140
Self-citationDiagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies
O'Brien, J. T., McKeith, I. G., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Marquardt, M., Reininger, C. B., & for the DLB Study Group (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.052050 · Cited by 140
Self-citationMitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 139
Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial
Grace, J., Daniel, S., Stevens, T., Shankar, K. K., Walker, Z., Byrne, E. J., Butler, S., Wilkinson, D. G., Woolford, J., Waite, J., et al. (2001) · International Psychogeriatrics · doi:10.1017/s104161020100758x · Cited by 138
Self-citationMemantine in Behavioral Variant Frontotemporal Dementia: Negative Results
Vercelletto, M., Boutoleau‐Bretonnière, C., Volteau, C., Puel, M., Auriacombe, S., Sarazin, M., Michel, B., Couratier, P., Thomas-Antérion, C., Verpillat, P., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101632 · Cited by 137
Minett, T., Thomas, A. J., Wilkinson, L., Daniel, S., Sanders, J., Richardson, J. L., Littlewood, E., Myint, P., Newby, J., & McKeith, I. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.995 · Cited by 137
Self-citationFord, A. H., & Almeida, O. P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111739 · Cited by 136
Ritchie, C. W., & Ritchie, K. A. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001893 · Cited by 136
Self-citationAn Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration
Boxer, A. L., Lipton, A. M., Womack, K. B., Merrilees, J. J., Neuhaus, J. M., Pavlic, D., Gandhi, A. D., Red, D., Martin-Cook, K., Svetlik, D. A., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318197852f · Cited by 132
The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.012 · Cited by 131
Pantoni, L., del Ser, T., Soglian, A., Amigoni, S., Spadari, G., Binelli, D., & Inzitari, D. (2005) · Stroke · doi:10.1161/01.str.0000155686.73908.3e · Cited by 130
Continuous intraventricular infusion of pentosan polysulfate: Clinical trial against prion diseases
Tsuboi, Y., Doh‐ura, K., & Yamada, T. (2009) · Neuropathology · doi:10.1111/j.1440-1789.2009.01058.x · Cited by 129
Ihl, R., Tribanek, M., Bachinskaya, N. Y., & for the GOTADAY Study Group (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1291217 · Cited by 128
Yancheva, S., Ihl, R., Nikolova, G., Panayotov, P., Schlaefke, S., Hoerr, R., & for the GINDON Study Group (2009) · Aging & Mental Health · doi:10.1080/13607860902749057 · Cited by 127
Cardwell, K., Hughes, C. M., & Ryan, C. A. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0310-9 · Cited by 127
Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features
Napryeyenko, O., & Borzenko, I. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296579 · Cited by 123
Coull, J. T., Sahakian, B. J., & Hodges, J. R. (1996) · Psychopharmacology · doi:10.1007/bf02246578 · Cited by 120
Non-invasive brain stimulation to assess and modulate neuroplasticity in Alzheimer's disease
Boggio, P. S., Valasek, C. A., Campanhã, C., Giglio, A. C. A., Baptista, N. I., Lapenta, O. M., & Fregni, F. (2011) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2011.617943 · Cited by 120
Vascular dementia: pharmacological treatment approaches and perspectives.
Baskys, A., & Hou, A. C. (2007) · PubMed · Cited by 114
Piracetam for dementia or cognitive impairment
Flicker, L. A., & Evans, J. G. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001011 · Cited by 113
Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt224 · Cited by 112
Ikeda, M., Mori, E., Matsuo, K., Nakagawa, M., & Kosaka, K. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0083-0 · Cited by 112
Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
Goldman, J. G., Goetz, C. G., Brandabur, M., Sanfilippo, M., & Stebbins, G. T. (2008) · Movement Disorders · doi:10.1002/mds.22322 · Cited by 109
Meeuwsen, E. J., Melis, R. J. F., van der Aa, G. C. H. M., Golüke-Willemse, G. A., Leest, B. J. M. D., van Raak, F. H. J. M., Schölzel-Dorenbos, C. J. M., Verheijen, D., Verhey, F. R. J., de Visser, M. C. H., et al. (2012) · BMJ · doi:10.1136/bmj.e3086 · Cited by 108
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C., MacKinley, J. D., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., BORRIE, M. J., Wells, J., Dziobek, I., Pasternak, S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001133 · Cited by 105
Kellermann, A. J., & Kloft, C. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.490 · Cited by 104
Projections of Future Numbers of Dementia Cases in Australia with and Without Prevention
Jorm, A. F., Dear, K. B. G., & Burgess, N. M. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2005.01713.x · Cited by 104
The impact of anticholinergic burden in Alzheimer's Dementia-the Laser-AD study
Fox, C., Livingston, G., Maidment, I., Coulton, S., Smithard, D. G., Boustani, M. A., & Katona, C. (2011) · Age and Ageing · doi:10.1093/ageing/afr102 · Cited by 102
Self-citationHo, R. C. M., Cheung, M. W. L., Fu, E., Win, H. H., Zaw, M. H., Ng, A., & Mak, A. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181f17eed · Cited by 99 · cited 2×
“Whilst cross-sectional studies have generally supported this view (Ho et al., 2011), prospective studies have not found a relationship between dementia and high homocysteine (Ho et al.”
BackgroundResultA 6‐month, open‐label study of memantine in patients with frontotemporal dementia
Diehl‐Schmid, J., Förstl, H., Perneczky, R., Pohl, C., & Kurz, A. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1973 · Cited by 97
Cummings, J. L., Froelich, L., Black, S. E., Bakchine, S., Bellelli, G., Molinuevo, J. L., Kressig, R. W., Downs, P., Caputo, A., & Strohmaier, C. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000340056 · Cited by 96
Oxford Textbook of Old Age Psychiatry
de Boer, M., Hertogh, C. M. P. M., Hendriks, S., Dening, T., Thomas, A. J., Stewart, R. J., & Taylor, J. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198807292.001.0001 · Cited by 91
Self-citationAdvances in the treatment of cognitive impairment in P arkinson's disease
Goldman, J. G., & Weintraub, D. A. (2015) · Movement Disorders · doi:10.1002/mds.26352 · Cited by 89
l -Dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia
Bonelli, S. B., Ransmayr, G. N., Steffelbauer, M., Lukas, T., Lampl, C., & Deibl, M. (2004) · Neurology · doi:10.1212/01.wnl.0000130194.84594.96 · Cited by 87
Wilkinson, D. G., & Andersen, H. F. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105162 · Cited by 87
Donepezil in the treatment of progressive supranuclear palsy
Fabbrini, G., Barbanti, P., Bonifati, V., Colosimo, C., Gasparini, M., Vanacore, N., & Meco, G. (2001) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2001.103002123.x · Cited by 84
Is it time to revisit the classification guidelines for primary progressive aphasia?
Mesulam, M. M., & Weıntraub, S. (2014) · Neurology · doi:10.1212/wnl.0000000000000272 · Cited by 84
GPs' attitudes, awareness, and practice regarding early diagnosis of dementia
Ahmad, S., Orrell, M. W., Iliffe, S., & Gracie, A. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x515386 · Cited by 83
Trazodone for agitation in dementia
Torres, G. M., Fioravanti, M., & Evans, J. G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004990 · Cited by 82
McKeith, I. G., Rowan, E. N., Askew, K., Naidu, A., Allan, L. M., Barnett, N. A., Lett, D. J., Mosimann, U. P., Burn, D. J., & O'Brien, J. T. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000216177.08010.f4 · Cited by 81
Self-citation
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationThe projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,666
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Metadata
- Authors
- O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., Sampson, E. L., Taylor, J.-P., Thomas, A., & Burns, A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-01-20
- Volume
- 31
- Issue
- 2
- Pages
- 147-168
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2090156874
- Cited by
- 354
- References
- 241
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.